Newton Biocapital

Newton Biocapital is a venture capital firm incorporated in Belgium, dedicated to financing biotech and life science projects in Europe and Japan for the prevention and treatment of chronic diseases. The firm supports promising start-up projects as well as neglected or undervalued late-stage projects, aiming to mitigate risks and create investor value. Their leadership team consists of specialists with extensive management and investor experience who guide bio-entrepreneurs through the development stages of their projects.

The firm's investment strategy focuses on projects that offer promising solutions for chronic health conditions, with an emphasis on alleviating patient and societal burdens. Newton Biocapital actively participates as board members, supporting portfolio companies in selecting preclinical and clinical programs across various technologies and disease areas. Their approach is hands-on, leveraging their expertise to help companies progress through the challenging early drug development phases up to proof of concept in patients.

Newton Biocapital has a track record of investing in companies such as DeuterOncology, a preclinical-stage biotech company developing a dual MET and RAS pathway inhibitor for targeted cancer therapies, and NeuVasQ Biotechnologies, a spin-off from the Université Libre de Bruxelles focused on restoring blood-brain barrier function in acute neurological disorders. The firm has also been instrumental in establishing spin-off companies like Epics Therapeutics and NeuVasQ Biotechnologies from leading universities in Belgium.